Study on Y-90, Capecitabine, and Atezolizumab for Treating Colorectal Cancer with Liver Metastases

Inclusion Criteria

• Diagnosed with colorectal cancer that has spread to the liver and cannot be surgically removed.
• Cancer must be measurable by scans and primarily located in the liver.
• Aged 18 years or older.
• In good general health, able to carry out daily activities with minimal restrictions.
• Cancer has progressed after trying at least two different treatments.
• Willing to provide tumor tissue and blood samples for research purposes.
• Less than 50% of the liver affected by cancer.
• Adequate blood, kidney, and liver function as shown by specific lab tests.
• Women of childbearing potential must use effective birth control during the study and for 6 months after.
• Men must use effective birth control during the study and for 3 months after.
• Able to understand and sign a consent form and follow study procedures.

Exclusion Criteria

• Previous treatment with Yttrium-90 or radiation to the liver.
• Life expectancy of less than 3 months.
• Certain genetic cancer markers or mutations.
• Cancer spread to the brain or abdomen, unless treated and stable.
• Recent participation in another clinical trial or treatment with certain drugs.
• History of severe heart or lung disease.
• Autoimmune diseases requiring treatment, except for certain stable conditions.
• Use of immunosuppressive medications recently or during the study.
• Active infections like HIV, hepatitis B or C, or tuberculosis.
• Recent major surgery or planning major surgery during the study.
• Pregnant or breastfeeding women.
• Other serious medical conditions that could interfere with the study.